Generic Name and Formulations:
Pralatrexate 20mg/mL; soln for IV inj; preservative-free.
Spectrum Pharmaceuticals, Inc.
Indications for FOLOTYN:
Relapsed or refractory peripheral T-cell lymphoma.
Prior to administration: mucositis should be ≤Grade 1, platelets should be ≥100,000/μL for first dose and ≥50,000/μL for subsequent doses, absolute neutrophil count should be ≥1,000/μL. Give by IV push over 3–5min. 30mg/m2 once weekly for 6 weeks in 7-week cycles. Continue until disease progression or unacceptable toxicity develops. Supplement with vitamin B12 (1mg IM every 8–10 weeks, starting within 10 weeks before first Folotyn dose) and folic acid (1–1.25mg orally daily, beginning 10 days before starting Folotyn and for 30 days after stopping). Severe renal impairment (CrCL 15–<30mL/min): 15mg/m2. Dose modifications for toxicities: see full labeling.
End stage renal disease (including dialysis): avoid, unless benefit justifies potential risk for toxicity. Omit and/or reduce dose to manage toxicities (eg, hematological, mucositis, hepatic impairment); see full labeling. Monitor CBCs and for mucositis at baseline and weekly. Monitor serum chemistry, renal and hepatic function before the 1st and 4th dose per cycle. Monitor for dermatological reactions; withhold dose or discontinue if severe. Monitor patients at increased risk of tumor lysis syndrome. Renal or hepatic impairment. Embryo-fetal toxicity. Pregnancy (Cat.D), nursing mothers: not recommended.
Folate analogue inhibitor.
May be potentiated by probenecid, NSAIDs, trimethoprim/sulfamethoxazole.
Mucositis, thrombocytopenia, neutropenia, anemia, abnormal liver function tests, nausea, fatigue, pyrexia, dehydration, sepsis, dyspnea; dermatological reactions (eg, skin exfoliation, ulceration, toxic epidermal necrolysis), tumor lysis syndrome.
Single-use vials (1mL, 2mL)—1
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|